Advertisement

Search Results

Advertisement



Your search for The ASCO matches 12394 pages

Showing 1 - 50


breast cancer
issues in oncology

FDA Issues Drug Safety Communication on Lung Inflammation Due to Treatment With CDK4/6 Inhibitors

On September 13, the U.S. Food and Drug Administration (FDA) issued a drug safety communication warning that palbociclib, ribociclib, and abemaciclib—used to treat some patients with advanced breast cancer—may cause rare but severe inflammation of the lungs. The agency approved new warnings about...

lung cancer
multiple myeloma
sarcoma

FDA Pipeline: Breakthrough Therapy Designation in Lung Cancer, Orphan Drug Designations in Myeloma and Soft-Tissue Sarcoma

Recently, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to tepotinib for metastatic non–small cell lung cancer harboring MET exon 14 skipping alterations, and Orphan Drug designations to novel chimeric antigen receptor T-cell therapies in both multiple myeloma ...

lung cancer

WCLC 2019: Video-Assisted Thoracic Surgery vs Open Surgery in Lung Cancer

Video-assisted thoracic surgery was associated with lower in-hospital complications and a shorter length of stay compared with open surgery among British patients who were diagnosed with early-stage lung cancer, according to research presented by Lim et al at the International Association for the...

lung cancer

WCLC 2019: Selpercatinib in RET Fusion–Positive NSCLC

Patients with RET fusion–positive non–small cell lung cancer (NSCLC) comprise up to 2% of all NSCLC cases, but there are no targeted therapies currently approved for patients with this form of lung cancer. Selpercatinib (also known as LOXO-292) is an oral and highly selective investigational drug...

lung cancer
immunotherapy

WCLC 2019: KEYNOTE-024 Survival Update Shows Benefit With Pembrolizumab vs Chemotherapy in Advanced NSCLC

First-line pembrolizumab monotherapy provides durable long-term overall survival benefit compared to chemotherapy in patients with advanced non–small cell lung cancer (NSCLC), according to data from the KEYNOTE-024 trial presented by Martin Reck, MD, PhD, at the International Association for the...

issues in oncology

WCLC 2019: Declaration From IASLC on Tobacco Cessation After Cancer Diagnosis

The International Association for the Study of Lung Cancer (IASLC) used the platform of the 2019 World Conference on Lung Cancer (WCLC) to call attention to the importance of tobacco cessation after cancer diagnosis and urged all physicians to screen patients with cancer for tobacco use and...

lung cancer
immunotherapy

WCLC 2019: Final Overall Survival Results of IMpower131 Trial in Advanced Squamous NSCLC

Patients with stage IV squamous non–small cell lung cancer (NSCLC) with high programmed cell death ligand 1 (PD-L1) expression treated with atezolizumab and chemotherapy experienced longer overall survival rates than those treated with chemotherapy alone. The data from the IMpower131 trial were...

lung cancer

WCLC 2019: BioMILD Trial of Blood MicroRNA Plus Low-Dose CT to Reduce CT Repeats in Lung Cancer Screening

Researchers from Milan reported that using a blood microRNA assay accompanied by low-dose computed tomography (CT) screening is safe and effective in screening patients for lung cancer. The results were shared at the International Association for the Study of Lung Cancer (IASLC) 2019 World...

lung cancer

WCLC 2019: Autoantibody Diagnostic Test Followed by CT Imaging May Improve Diagnosis, Reduce Mortality in Lung Cancer

A combination of the EarlyCDT-Lung Test followed by computed tomography (CT) imaging in Scottish patients at risk for lung cancer resulted in a significant decrease in late-stage diagnosis of lung cancer and may decrease lung cancer–specific mortality, according to research presented at...

issues in oncology
global cancer care

Michael Kenneth Keng, MD, on an ASCO Quality Training Program: 5-Year Review

Michael Kenneth Keng, MD, of the University of Virginia, gives a status update on this international program, and discusses future initiatives which include coaching mentorship and publishing articles on quality care (Abstract 7).

issues in oncology

Cary P. Gross, MD, on Creating and Implementing Clinical Pathways: Where is the Patient’s Voice?

Cary P. Gross, MD, of Yale School of Medicine, discusses the challenges of implementing pathways and guiding patient decision-making on treatment.

issues in oncology

Joseph O. Jacobson, MD, on Suffering, Systems, and Safety: The Joseph V. Simone Award Lecture

Joseph O. Jacobson, MD, of Dana-Farber Cancer Institute, and this year’s recipient of the award for excellence in quality cancer care, discusses the need for quality improvement (QI) to encompass systems of care, the role of QI in preventing suffering, how poor quality affects patient safety, and...

issues in oncology

Nadine Housri, MD, on Online Tumor Boards: A New Resource for Practicing Oncologists

Nadine Housri, MD, of the Yale School of Medicine, talks about a new paradigm in information sharing: tumor board discussions, recorded at NCI-designated comprehensive cancer centers, which can be viewed by community and other oncologists. Currently, thoracic, breast, and GI cancers are included,...

issues in oncology

Matthew B. Schabath, PhD, on Addressing Cultural Barriers to Equality in Oncology Among Sexual Gender Minorities

Matthew B. Schabath, PhD, of H. Lee Moffitt Cancer Center and Research Institute, discusses the disparities in cancer care among members of the LGBTQ community and the need to collect more data in order to close that gap.

symptom management

Angela M. Stover, PhD, on Patient-Reported Outcome Performance Measures for Oncology Practice

Angela M. Stover, PhD, of the University of North Carolina at Chapel Hill, discusses ASCO’s initiative to develop patient-based performance measures for assessing and managing symptoms. The measures have made substantial differences in reducing nausea, constipation, and insomnia (Abstract 173).

issues in oncology

Lauren M. Hamel, PhD, on Race and Doctor-Patient Behavior

Lauren M. Hamel, PhD, of Wayne State University/Karmanos Cancer Institute, discusses her findings on the ways in which nonverbal behavior between doctors and patients of the same or different races can affect their relationship, quality of communication, and ultimately, perhaps outcomes as well...

issues in oncology

Mallika Sharma, MPH, on Eliminating Prior Authorizations, Anxiety, Delay in Care, Higher Costs

Mallika Sharma, MPH, of Seattle Cancer Care Alliance, discusses her findings that, by doing away with the many prior authorization denials based on administrative errors, providers may offer higher-value care by eliminating unnecessary anxiety among patients, administrative burdens, and increased...

issues in oncology

Grace C. Hillyer, EdD, MPH, on Enrolling Patients in Clinical Trials: Improving Clinician-Patient Communication

Grace C. Hillyer, EdD, MPH, of Columbia University Mailman School of Public Health, discusses the many barriers to enrolling patients in clinical trials, most notably different attitudes toward and perceptions about research studies among clinicians vs patients. Her findings point to the need for...

issues in oncology

Elena Martinez, PhD, MPH, on Diversity in Precision Oncology

Elena Martinez, PhD, MPH, of Moores Cancer Center at the University of California, San Diego, discusses the challenges of ensuring diversity in precision oncology and potential solutions to address the challenges.

issues in oncology

Oncology Communications Online: Pause and Think Before Hitting ‘Send’

The emergence of online technologies over the past few decades has fundamentally changed the way society communicates and shares information. This sea change has also had profound influence on the practice of medicine, from real-time information-sharing among colleagues, to having instant access...

cost of care
issues in oncology

Ryan Huey, MD, on the Financial Toxicity of Early-Phase Clinical Trials

Ryan Huey, MD, of The University of Texas MD Anderson Cancer Center, discusses his findings that showed the large financial burden on lower-income patients enrolled in phase I trials (Abstract 8).

lung cancer

Cristina Merkhofer, MD, MHS, on NSCLC: Survival Impact of Taking Part in a Clinical Trial

Cristina Merkhofer, MD, MHS, of Fred Hutchinson Cancer Research Center, discusses study results showing that for patients with metastatic non–small cell lung cancer at her institution, enrolling in a therapeutic drug clinical trial was associated with a 47% lower risk of death, compared with not...

cost of care
lung cancer

Bernardo H.L. Goulart, MD, on Stage IV NSCLC: High Drug Costs May Affect Survival

Bernardo H. L. Goulart, MD, of Seattle Cancer Care Alliance, discusses his findings that high out-of-pocket costs for oral tyrosine kinase inhibitors may lower survival rates, shorten the duration of therapy, and reduce the number of prescriptions for patients with metastatic EGFR- or ALK-positive...

lung cancer

WCLC 2019: Screening Efficacy of PLCOm2012 vs USPSTF Criteria

Researchers reported that a prospective trial comparing two screening methods for patients at risk of developing lung cancer found that a model used by Canadian, Australian, and European public health organizations detected more cancers than the screening model used by the United States Preventive...

gynecologic cancers

Olaparib Monotherapy Improves Outcomes in BRCA-Mutated, Platinum-Sensitive Relapsed Ovarian Cancer

Compared with treatment with nonplatinum-based chemotherapy, monotherapy with the PARP (poly [ADP ribose] polymerase) inhibitor olaparib led to statistically significant and clinically relevant improvements in overall response rate and progression-free survival in women with germline BRCA-mutated, ...

lung cancer
issues in oncology

WCLC 2019: Survey Findings on Evidence-Based Guidelines for Molecular Testing in Lung Cancer

One-third of those who responded to a survey reported they are unaware of evidence-based guidelines that support the use of molecular testing in lung cancer, according to results from the International Association for the Study of Lung Cancer (IASLC) Global Survey on Molecular Testing in Lung...

2019 Lasker Awards for Basic and Clinical Medical Research and Public Service Announced

On September 10, The Lasker Foundation announced the winners of its 2019 Lasker Awards: Max D. Cooper, MD, of Emory University, and Jacques Miller, AC, FRS, FAA, of the Walter and Eliza Hall Institute of Medical Research, will receive the Albert Lasker Basic Medical Research Award; H. Michael...

lung cancer
immunotherapy

WCLC 2019: CASPIAN Trial Finds Addition of Durvalumab to Chemotherapy Improves Overall Survival in Patients With Extensive-Stage SCLC

The addition of durvalumab to chemotherapy improved overall survival in patients with extensive-stage small cell lung cancer (SCLC), according to research presented at the International Association for the Study of Lung Cancer (IASLC) 2019 World Conference on Lung Cancer (WCLC) (Abstract PL02.11)....

lung cancer
immunotherapy

WCLC 2019: Pooled Analysis of CheckMate 017 and 057: 5-Year Outcomes With Nivolumab vs Docetaxel in Previously Treated NSCLC

Pooled data on two clinical trials demonstrated patients with previously treated non–small cell lung cancer (NSCLC) treated with nivolumab had a greater than fivefold increase in 5-year overall survival rate compared to treatment with the chemotherapy docetaxel. Scott Gettinger, MD, of Yale...

Erratum

In the August 10, 2019, issue of The ASCO Post, a photo on page 39, in an article about the National Comprehensive Cancer Network (NCCN) Policy Summit, was incorrectly identified as Terrell Johnson, MPA, an NCCN Policy and Advocacy Fellow. We regret the error and apologize to Mr. Johnson for the...

issues in oncology

FDA Proposes New Required Health Warnings With Images for Cigarette Packages and Advertisements

On August 15, the U.S. Food and Drug Administration (FDA) issued a proposed rule to require new health warnings on cigarette packages and in advertisements to promote greater public understanding of the negative health consequences of smoking. The proposed warnings, which feature photo-realistic...

John Hansen, MD, Transplant Expert Who Founded Volunteer Donor Registries, Dies at 76

Over the past few decades, our understanding of transplant immunology has moved from basic allograft rejection to the current molecular level that offers life-saving treatments for patients with cancer. The scientific elegance of this remarkable therapy’s arc from experimental to standard of care...

leukemia

Having Cancer as a Teenager Derailed My Life Course

In 1994, I was a normal, active 15-year-old, who loved cars, sports, and rock music, especially songs from my favorite group, The Clash. In fact, it was while jubilantly dancing alone in my room to one of their tunes that I vomited into my hands, an early symptom of acute myeloid leukemia (AML). I...

A Vigorous Life Through the Prism of Impending Death

“Live while you’re living, friends,” writes Julie Yip-­Williams in her memoir, The Unwinding of the Miracle: A Memoir of Life, Death, and Everything That Comes After. It was The New York Times bestseller when she died of stage IV colon cancer at the age of 42. She is the most recent of several...

Not for the Squeamish: Surgery in the 19th Century

Imagine undergoing major surgery in a grimy operating room without any form of antisepsis. That was the grim reality in the 1800s, when the ruling theory was that damage from “bad air” was responsible for infections in surgical wounds. Hospitals simply aired out the surgical wards at midday to...

Florida Cancer Specialists Welcomes Luis Carrascosa, MD

Florida Cancer Specialists & Research Institute recently announced that radiation oncologist Luis Carrascosa, MD, has joined the statewide practice. Dr. Carrascosa has privileges at Ocala Regional Medical Center, West Marion Community Hospital, and AdventHealth Ocala. Dr. Carrascosa earned his ...

immunotherapy
gastroesophageal cancer

Pembrolizumab in Advanced Esophageal Squamous Cell Cancer With PD-L1 Expression of CPS ≥ 10

On July 30, 2019, pembrolizumab was approved for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express programmed cell death ligand 1 (PD-L1; Combined Positive Score [CPS] ≥ 10), as determined by a U.S. Food and Drug...

Doctor, Where Art Thou?

The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...

Nakul Singhal, MD, and Nicole Carreau, MD, Join New York Cancer & Blood Specialists

Oncologist Nakul Singhal, MD, has joined New York Cancer & Blood Specialists (NYCBS) and will be accepting new patients at the Bayside and New Hyde Park locations. NYCBS also welcomes oncologist Nicole Carreau, MD. Prior to joining NYCBS, Dr. Singhal practiced at Hackensack Meridian Health...

Steven A. Rosenberg, MD, PhD, Awarded for His Pioneering Work in Immunotherapy

The Edogawa-NICHE Committee recently announced that the 2019-Edogawa NICHE Prize has been awarded to Steven A. Rosenberg, MD, PhD, for his work in developing effective adoptive immunotherapies and genetically modified T cells. Dr. Rosenberg’s research has significantly contributed to the...

issues in oncology

Confronting the Criticisms Facing Watson for Oncology

Over the past 2 years, IBM’s Watson for Oncology cognitive computing system, which uses artificial intelligence (AI) algorithms to generate treatment recommendations, has come under fire for allegedly not delivering on expectations to provide state-of-the-art personalized treatment for patients...

MD Anderson to Expand Proton Therapy Center

The University of Texas MD Anderson Cancer Center recently unveiled plans to expand its Proton Therapy Center. The expansion will more than double the center’s size to more than 160,000 square feet. The estimated completion of the new building is November 2023. The $159 million expansion will...

FDA OCE and Syapse Announce Research Collaboration Focused on Regulatory Use of Real-World Evidence

Syapse and the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) have signed a multiyear research collaboration agreement focused on the use of real-world evidence to support regulatory decision-making. Syapse and the OCE will work with stakeholders across the FDA to...

American Cancer Society Names William G. Cance, MD, Chief Medical and Scientific Officer

William G. Cance, MD, has been selected as he Chief Medical and Scientific Officer of the American Cancer Society (ACS). Dr. Cance will lead the integration of the ACS Research and Cancer Control departments, unifying its intramural and extramural research; prevention and early detection; patient...

issues in oncology

Firing Your Patient: How to Terminate a Treatment Relationship

Many clinicians are confused by the evolving opioid prescribing guideline issued by the Centers for Disease Control and Prevention (CDC) meant to stem the rising epidemic of opioid addiction and overdose in the United States.1 Many are also worried about regulatory oversight by the U.S. Drug...

Bert Vogelstein, MD, and Irving L. Weissman, MD, Recognized for Revolutionizing Cancer Research

Two scientists, whose discoveries in stem cell and cancer cell biology have led to innovative advances in fields ranging from oncology and immunology to cancer genomics and regenerative medicine, will receive the 2019 Albany Medical Center Prize in Medicine and Biomedical Research. Bert Vogelstein, ...

Women Who Conquer Cancer: Featured Conversations

The Conquer Cancer “Your Stories” mini-podcast series shares unscripted conversations among patients, doctors, and the family and friends who conquer cancer with them. Developed by Conquer Cancer, the series also includes transcripts of conversations. In one such featured conversation, Christina...

Spotlight on Women Who Conquer Cancer

Women Who Conquer Cancer (WWCC) is a groundbreaking program that is committed to supporting early-career female researchers by funding research grants through Conquer Cancer, the ASCO Foundation. Since its inception 6 years ago, the program has raised over $4 million, has funded 21 Young...

Stock Your Practice With ASCO Answers Materials

ASCO has created helpful resources to support your patients and their caregivers. ASCO Answers patient education materials provide trusted information on cancer types, diagnosis, treatment, side effects, and coping in three convenient formats: fact sheets, topic-specific booklets, and comprehensive ...

ASCO Welcomes 2019–2020 Leadership Development Program Participants, Education Scholars

ASCO is pleased to announce the 2019–2020 participants in its Leadership Development Program and Education Scholars Program. Leadership Development Program The ASCO Leadership Development Program, which began in 2009, is a year-long program designed to train future leaders in oncology by supporting ...

Advertisement

Advertisement



Advertisement